Bajaj Healthcare Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bajaj Healthcare Ltd is ₹ 274.95 as of 18 May 15:30 . The P/E Ratio of Bajaj Healthcare Ltd changed from 7.8 on March 2021 to 53.7 on March 2025 . This represents a CAGR of 47.09% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 years The Market Cap of Bajaj Healthcare Ltd changed from ₹ 650.77 crore on March 2021 to ₹ 2121 crore on March 2025 . This represents a CAGR of 26.66% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 years The revenue of Bajaj Healthcare Ltd for the Mar '26 is ₹ 156.01 crore as compare to the Dec '25 revenue of ₹ 162.87 crore. This represent the decline of -4.21% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The ebitda of Bajaj Healthcare Ltd for the Mar '26 is ₹ -11.05 crore as compare to the Dec '25 ebitda of ₹ 31.9 crore. This represent the decline of -134% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The net profit of Bajaj Healthcare Ltd changed from ₹ 7.13 crore to ₹ -22.85 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The Dividend Payout of Bajaj Healthcare Ltd changed from 4.57 % on March 2021 to 7.99 % on March 2025 . This represents a CAGR of 11.82% over 5 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 years .

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

FAQs for the comparison of Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, Bajaj Healthcare Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of Bajaj Healthcare Ltd is 925 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,343 Cr

What are the key factors driving the stock performance of Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd?

As of May 18, 2026, the Bajaj Healthcare Ltd stock price is INR ₹274.95. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹200.15.

How do dividend payouts of Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bajaj Healthcare Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.